Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Durvalumab - Celgene/MedImmune

Drug Profile

Durvalumab - Celgene/MedImmune

Alternative Names: Anti-PD-L1 monoclonal antibody; Anti-PD-LI mAb; Anti-programmed cell death 1 ligand 1 monoclonal antibody; Imfimzi; Imfinzi; MEDI-4736

Latest Information Update: 03 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune
  • Developer Advaxis; AIO Studien gGmbH; AstraZeneca; AVEO Oncology; Big Ten Cancer Research Consortium; Canadian Cancer Trials Group; Case Comprehensive Cancer Center; Celgene International SARL; Centre hospitalier de l'Universite de Montreal; Centre Leon Berard; Charite - Universitatsmedizin Berlin; Childrens Hospital Los Angeles; Dana-Farber Cancer Institute; Eli Lilly and Company; Fondazione IRCCS Istituto Nazionale dei Tumori; GlaxoSmithKline; Gradalis; Grand Hopital de Charleroi; Grupo Espanol de Tumores Neuroendocrinos; Gustave Roussy; Immunocore; Innate Pharma; Institut Claudius Regaud; Jules Bordet Institute; Juno Therapeutics; Kyoto Breast Cancer Research Network; Ludwig Institute for Cancer Research; M. D. Anderson Cancer Center; MedImmune; Memorial Sloan-Kettering Cancer Center; Mirati Therapeutics; Myriad Genetic Laboratories; National Cancer Institute (USA); National Health and Medical Research Council; Northwestern University; Pharmacyclics; Plexxikon; Radboud University; Samsung Medical Center; Spanish Oncology Genito-Urinary Group; Swiss Group for Clinical Cancer Research; UNC Lineberger Comprehensive Cancer Center; UNICANCER; University College London; University of Colorado at Denver; University of Kansas Medical Center; University of Maryland Greenbaum Cancer Center; University of Southern California; University of Sydney; University of Texas M. D. Anderson Cancer Center; VentiRx Pharmaceuticals; Washington University School of Medicine; Yale University; Yonsei University College of Medicine
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer; Urogenital cancer
  • Phase III Biliary cancer; Bladder cancer; Cervical cancer; Fallopian tube cancer; Head and neck cancer; Liver cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours
  • Phase II/III Breast cancer; Gynaecological cancer; Pancreatic cancer
  • Phase II Acute myeloid leukaemia; Brain metastases; Cholangiocarcinoma; Colorectal cancer; Diffuse large B cell lymphoma; Endometrial cancer; Gallbladder cancer; Gastric cancer; Germ cell and embryonal neoplasms; Glioblastoma; Mesothelioma; Multiple myeloma; Myelodysplastic syndromes; Neuroendocrine tumours; Oesophageal cancer; Oropharyngeal cancer; Prostate cancer; Sarcoma; Soft tissue sarcoma
  • Phase I/II Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Haematological malignancies; Lung cancer; Lymphoma; Malignant melanoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Renal cancer
  • Phase I CNS cancer; Gastrointestinal cancer; Lymphoproliferative disorders; Thyroid cancer; Vulvovaginal cancer

Most Recent Events

  • 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
  • 12 Nov 2019 AstraZeneca completes a phase I trial in Breast cancer (Adjunctive treatment, Second-line therapy or greater, Metastatic disease, Late-stage disease, Inoperable/Unresectable, Recurrent, In adults, In the elderly) in Canada (IV) (NCT02649686)
  • 30 Oct 2019 Medimmune plans a phase II COLUMBIA-2 trial for Microsatellite-stable colorectal Cancer (Combination therapy, adjuvant therapy, First-line therapy) in the US, Canada, France and Spain (IV)(NCT04145193)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top